2026.11.22 (일)

  • 맑음속초2.7℃
  • 구름많음-4.5℃
  • 맑음철원-4.3℃
  • 맑음동두천-1.8℃
  • 흐림파주-3.0℃
  • 맑음대관령-5.0℃
  • 구름많음춘천-3.8℃
  • 맑음백령도6.9℃
  • 맑음북강릉2.5℃
  • 맑음강릉4.0℃
  • 맑음동해-0.2℃
  • 구름많음서울0.9℃
  • 구름많음인천3.4℃
  • 맑음원주-1.9℃
  • 맑음울릉도4.6℃
  • 맑음수원0.4℃
  • 맑음영월-3.7℃
  • 맑음충주-3.1℃
  • 맑음서산1.9℃
  • 맑음울진3.6℃
  • 맑음청주2.4℃
  • 맑음대전0.4℃
  • 맑음추풍령-3.0℃
  • 맑음안동-1.8℃
  • 맑음상주-1.4℃
  • 맑음포항2.5℃
  • 맑음군산1.1℃
  • 맑음대구0.4℃
  • 맑음전주1.4℃
  • 맑음울산0.8℃
  • 맑음창원3.7℃
  • 맑음광주3.2℃
  • 맑음부산4.9℃
  • 맑음통영4.2℃
  • 맑음목포5.2℃
  • 맑음여수5.4℃
  • 맑음흑산도6.2℃
  • 맑음완도4.1℃
  • 맑음고창0.7℃
  • 맑음순천-2.0℃
  • 맑음홍성(예)0.1℃
  • 맑음-1.5℃
  • 맑음제주7.0℃
  • 맑음고산7.1℃
  • 맑음성산4.0℃
  • 맑음서귀포7.4℃
  • 맑음진주-0.8℃
  • 구름많음강화2.5℃
  • 맑음양평-1.5℃
  • 맑음이천-2.3℃
  • 맑음인제-4.3℃
  • 맑음홍천-3.3℃
  • 맑음태백-3.2℃
  • 맑음정선군-3.8℃
  • 맑음제천-5.7℃
  • 맑음보은-3.0℃
  • 맑음천안-2.0℃
  • 맑음보령4.5℃
  • 맑음부여-0.9℃
  • 맑음금산-1.6℃
  • 맑음-0.1℃
  • 맑음부안1.6℃
  • 맑음임실-1.6℃
  • 맑음정읍0.4℃
  • 맑음남원-0.5℃
  • 맑음장수-2.8℃
  • 맑음고창군0.7℃
  • 맑음영광군1.0℃
  • 맑음김해시2.2℃
  • 맑음순창군-0.9℃
  • 맑음북창원2.2℃
  • 맑음양산시0.5℃
  • 맑음보성군1.1℃
  • 맑음강진군1.0℃
  • 맑음장흥-0.6℃
  • 맑음해남0.5℃
  • 맑음고흥-0.6℃
  • 맑음의령군-2.2℃
  • 맑음함양군-2.3℃
  • 맑음광양시3.3℃
  • 맑음진도군1.2℃
  • 맑음봉화-6.1℃
  • 맑음영주-3.1℃
  • 맑음문경-1.6℃
  • 맑음청송군-5.2℃
  • 맑음영덕3.3℃
  • 맑음의성-3.2℃
  • 맑음구미-1.2℃
  • 맑음영천-2.1℃
  • 맑음경주시-2.1℃
  • 맑음거창-2.6℃
  • 맑음합천-0.6℃
  • 맑음밀양-0.7℃
  • 맑음산청-0.8℃
  • 맑음거제2.2℃
  • 맑음남해4.1℃
  • 맑음0.6℃
기상청 제공
Shoppy 로고
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
  • 해당된 기사를 공유합니다

European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares

EC grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which demonstrated that over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose[1,2]
Generalized pustular psoriasis (GPP) differs significantly from plaque psoriasis in both its disease mechanism and severity[2,3,4]
The EMA’s decision builds on existing approvals in the USA and Japan[5]

The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults.[1] Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP.[2, 4-7]

“The symptoms of GPP are devastating and cause immense pain as well as hospitalization during a flare. Increased GPP awareness that leads to accurate and faster diagnosis is one important step to improving the quality of life for people living with GPP,” said Frida Dunger Johnsson, Executive Director, IFPA. “Now with a specifically developed treatment, people living with GPP can be offered a new lease of life by effectively managing the impact of GPP flares.”

“We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases which we are investigating in further clinical trials” commented Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim. “Today’s news marks the first of what we hope will be a number of new treatment options from our accelerated late-stage portfolio with the potential to transform the lives of people for generations to come.”

The EC’s conditional approval of spesolimab is based on results from the pivotal EFFISAYIL® 1 Phase II clinical trial.[2] In the 12-week trial, patients experiencing a GPP flare were treated with spesolimab or placebo. Most patients at the outset of the trial had a moderate or severe pustulation of the skin. After one week, 54% of patients treated with a single dose of spesolimab showed no visible pustules compared to placebo (6%).[2] Adverse events were reported in 66% of patients treated with spesolimab and 56% of those receiving placebo after one week.[2] Infections were reported by 17% and 6% of patients in the spesolimab and placebo groups respectively (at week one).2 Serious adverse events were reported in 6% of patients treated with spesolimab (at week one).[2]

People living with GPP often do not receive a correct or timely diagnosis and may have their symptoms identified as other forms of psoriasis. A Global Delphi Consensus Project classified GPP as phenotypically, genetically, immunologically and histopathologically distinct from psoriasis vulgaris / plaque psoriasis based on a systematic literature review.[3] The growing list of regulatory approvals for spesolimab for the treatment of GPP flares underlines that the Delphi panel’s vision of improved diagnosis and treatment for people with GPP is increasingly achievable.

For the full press release and link to ‘Notes to Editors’ please click here:

Press release https://bit.ly/3j0BFfQ

Additional information

www.boehringer-ingelheim.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005586/en/

언론연락처: Boehringer Ingelheim Corporate Communications Media + PR Laura Lessenich +49 (6132) 77-173436

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.




포토

 
모바일 버전으로 보기